Answers are grounded in this paper and cite their sources.
Background and Objectives: Duchenne muscular dystrophy (DMD) is a progressive neuromuscular disorder caused by DMD pathogenic variants, leading to dystrophin deficiency, muscle degeneration, loss of ambulation, respiratory failure, and reduced life expectancy. Current treatments, such as corticosteroids and supportive care, offer limited long-term benefits. Delandistrogene moxeparvovec is a promising gene therapy developed to restore dystrophin expression and deliver microdystrophin to skeletal and cardiac muscles. This systematic review and meta-analysis evaluate the efficacy of this treatment in ambulatory pediatric patients with DMD. Methods: A systematic search of Cochrane, PubMed, and Embase identified randomized controlled trials (RCTs) and cohort studies on delandistrogene moxeparvovec in ambulatory male children (≥4 to <8 years) with DMD. Primary outcomes included NSAA score changes, a 10-meter walk/run test (10MWR), time to rise (TTR), and dystrophin expression. Study selection followed PRISMA guidelines, and statistical analyses were conducted using R software. The study was registered in PROSPERO (CRD42025635605). Discussion: Delandistrogene moxeparvovec, despite high heterogeneity for the analysis, improved functional outcomes in ambulatory pediatric patients with DMD. Further long-term RCTs are needed to confirm its safety and efficacy.
No takes yet. Share an insight, caveat, or question.
Antonello et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: